Scientific Reports (Jul 2022)

Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19

  • Thomas Robert,
  • Guillaume Lano,
  • Noémie Resseguier,
  • Mickaël Bobot,
  • Dammar Bouchouareb,
  • Stéphane Burtey,
  • Xavier de Lamballerie,
  • Jean Dhorne,
  • Bertrand Dussol,
  • Ariane Duval,
  • Julien Faraut,
  • Toscane Fourié,
  • Philippe Giaime,
  • Mourad Hallah,
  • Dominique Jaubert,
  • Océane Jéhel,
  • Tristan Legris,
  • Stéphane Liotatis,
  • Valérie Moal,
  • Laetitia Ninove,
  • Nathalie Pedinielli,
  • Marion Pelletier,
  • Manon Romeu-Giannoli,
  • Mariela Saba,
  • Marion Sallée,
  • Laurent Samson,
  • Adriana Saveanu,
  • Violaine Scarfoglière,
  • Pascale Sebahoun,
  • Romain Vial,
  • Clarissa Von Kotze,
  • Philippe Brunet,
  • Gaëtan Lebrun,
  • Stanislas Bataille,
  • Noémie Jourde-Chiche

DOI
https://doi.org/10.1038/s41598-022-15913-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Hemodialysis (HD) patients are at risk for severe COVID-19 and cannot comply with social distancing. SARS-COV2 seroprevalence in French patients and caregivers after the first wave of COVID-19 is unknown. SeroCOVIDial is a prospective study conducted between June and December 2020. SARS-COV2 seroprevalence was evaluated by a rapid serological test (BIOSYNEX) in HD patients and caregivers, and the presence or not of anti-SARS-COV2 neutralizing or non-neutralizing antibodies in patients was also determined by ELISA and seroneutralization. In June 2020, 451 HD patients and 238 caregivers were included. Overall SARS-COV2 seroprevalence was 8.4% (patients) and 6.7% (caregivers), and was 87.1% (patients) and 90.0% (caregivers) in participants with a previously documented SARS-COV2 infection. Overall seroprevalence reached 13.8% (patients) and 12.6% (caregivers) following the second epidemic wave. During the follow-up, 38 (8.4%) patients died (9 of COVID-19). Among the 44 (10.6%) patients who became infected, only two were seropositive at M0. The levels of anti-SARS-COV2 antibodies decreased over time in patients and caregivers. The BIOSYNEX test showed 82.9% sensitivity and 97.7% specificity. Prevalence of anti-SARS-COV2 antibodies was low in HD patients and caregivers after the first epidemic wave but rose after the second wave. A rapid serological test showed good performances and could be useful for future monitoring of anti-SARS-COV2 antibodies.